




RealRate

PHARMACEUTICAL 2023

Bellicum Pharmaceuticals INC
Rank 239 of 471



The relative strengths and weaknesses of Bellicum Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Bellicum Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 91% points. The greatest weakness of Bellicum Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 13% points above the market average of 245%.

Input Variable	Value in 1000 USD
Assets, Current	23,801
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,772
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	-16
Other Expenses	2.0
Other Liabilities	0
Other Net Income	2,010
Other Revenues	1,500
Property and Equipment	22
Research and Development	22,764
Selling, General and Administrative Expense	5,717

Output Variable	Value in 1000 USD
Assets	23,823
Liabilities	3,772
Expenses	28,483
Revenues	1,500
Stockholders Equity	20,051
Net Income	-24,973
Comprehensive Net Income	-24,981
BaseVar	29,802
ECR before LimitedLiability	136%
Economic Capital Ratio	257%